Clinical Trial Detail

NCT ID NCT04098068
Title Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.